Medipal Holdings Corp
F:59Z

Watchlist Manager
Medipal Holdings Corp Logo
Medipal Holdings Corp
F:59Z
Watchlist
Price: 15.3 EUR -0.65% Market Closed
Market Cap: €3.2B

Wall St Price Targets

59Z Price Targets Summary
Medipal Holdings Corp

Wall Street analysts forecast 59Z stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 59Z is 15.58 EUR with a low forecast of 14.34 EUR and a high forecast of 17.54 EUR.

Lowest Forecast
Price Target
14.34 EUR
6% Downside
Average Forecast
Price Target
15.58 EUR
2% Upside
Highest Forecast
Price Target
17.54 EUR
15% Upside
Medipal Holdings Corp Competitors:
Price Targets
WRLD
World Acceptance Corp
-21% Downside

Revenue
Forecast

2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 4 years is 3%.

Gross Profit
Forecast

2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 2%. The projected CAGR for the next 3 years is 3%.

Operating Income
Forecast

8% / Year
Past Growth
-8% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
8% / Year
Past Growth
-8% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 13 years is -8%.

Pre-Tax Income
Forecast

9% / Year
Past Growth
0% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
9% / Year
Past Growth
0% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 9%. The projected CAGR for the next 3 years is 0%.

Net Income
Forecast

10% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat
10% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat

Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 3 years is 1%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 59Z's stock price target?
Price Target
15.58 EUR

According to Wall Street analysts, the average 1-year price target for 59Z is 15.58 EUR with a low forecast of 14.34 EUR and a high forecast of 17.54 EUR.

What is the Revenue forecast for Medipal Holdings Corp?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 4 years is 3%.

What is the Gross Profit forecast for Medipal Holdings Corp?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 2%. The projected CAGR for the next 3 years is 3%.

What is the Operating Income forecast for Medipal Holdings Corp?
Projected CAGR
-8%

Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 13 years is -8%.

What is the Pre-Tax Income forecast for Medipal Holdings Corp?
Projected CAGR
0%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 9%. The projected CAGR for the next 3 years is 0%.

What is the Net Income forecast for Medipal Holdings Corp?
Projected CAGR
1%

Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 3 years is 1%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett